Efficacy of butyric acid preparations in patients with hepatocellular carcinoma undergoing chemotherapy
Phase 3
Recruiting
- Conditions
- nresectable hepatocellular carcinomaUnresectable HCC
- Registration Number
- JPRN-jRCTs061230077
- Lead Sponsor
- Otsuka Motoyuki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
1 18 age old over
2 Regardless of gender
3 Patients diagnosed with unresectable hepatocellular carcinoma
4 Patients who will receive treatment with Durvalumab and Tremelimumab
5 Patients who have been fully informed consent
Exclusion Criteria
1 Patients with Child-Pugh score over 8
2 Patients used to have hypersensitivity with butyric acid
3 Being pregnant or possibly pregnant
4 Patients who judged as inappropriate candidate by the chief medical examine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method 1 Response rate<br>2 Disease cotrol rate<br>3 Overall survival<br>4 Change of intestinal flora<br>5 Adverse Events and side effects